The Influence of Socioeconomic Status on Racial/Ethnic Disparities among the ER/PR/HER2 Breast Cancer Subtypes

Journal of Cancer Epidemiology
Carol Parise, Vincent Caggiano

Abstract

Background. The eight ER/PR/HER2 breast cancer subtypes vary widely in demographic and clinicopathologic characteristics and survival. This study assesses the contribution of SES to the risk of mortality for blacks, Hispanics, Asian/Pacific Islanders, and American Indians when compared with white women for each ER/PR/HER2 subtype. Methods. We identified 143,184 cases of first primary female invasive breast cancer from the California Cancer Registry between 2000 and 2012. The risk of mortality was computed for each race/ethnicity within each ER/PR/HER2 subtype. Models were adjusted for tumor grade, year of diagnosis, and age. SES was added to a second set of models. Analyses were conducted separately for each stage. Results. Race/ethnicity did not contribute to the risk of mortality for any subtype in stage 1 when adjusted for SES. In stages 2, 3, and 4, race/ethnicity was associated with risk of mortality and adjustment for SES changed the risk only in some subtypes. SES reduced the risk of mortality by over 45% for American Indians with stage 2 ER+/PR+/HER2- cancer, but it decreased the risk of mortality for blacks with stage 2 triple negative cancer by less than 4%. Conclusions. Racial/ethnic disparities do not exist in all E...Continue Reading

References

Aug 30, 2000·Nature·C M PerouD Botstein
Mar 29, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Linda C HarlanRachel Ballard-Barbash
Apr 4, 2002·Journal of the National Cancer Institute·Cathy J BradleyCaralee Roberts
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher I LiKathleen E Malone
Jun 28, 2003·Proceedings of the National Academy of Sciences of the United States of America·Therese SorlieDavid Botstein
Mar 17, 2005·Journal of the National Cancer Institute·Rowan T ChlebowskiRoss Prentice
Jun 9, 2005·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Christina A ClarkeAntoinette Stroup
Sep 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dawn HershmanAlfred I Neugut
Feb 21, 2006·Cancer Causes & Control : CCC·Arti Parikh-PatelRatnali V Jain
Mar 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lisa A NewmanGraham A Colditz
Mar 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nina A BickellAmber A Guth
Jun 8, 2006·JAMA : the Journal of the American Medical Association·Lisa A CareyRobert C Millikan
Jun 20, 2006·Cancer Causes & Control : CCC·Scarlett L Gomez, Sally L Glaser
Oct 31, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN St Gallen Expert Panel Members
Jan 24, 2007·Breast Cancer Research : BCR·Lisa K DunnwaldChristopher I Li
Mar 21, 2007·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Jason A ZellHoda Anton-Culver
Jul 31, 2007·Breast Cancer Research and Treatment·Mary Jo LundJ William Eley
Apr 9, 2008·American Journal of Clinical Oncology·Xianglin L DuTamra E Meyer
Dec 17, 2008·The Journal of Surgical Research·Anjali D DeshpandeJulie A Margenthaler
Mar 27, 2009·Breast Cancer Research : BCR·Lesley A SteadCarol L Rosenberg
Jun 12, 2009·Journal of Women's Health·Linda Vona-Davis, David P Rose
Jul 9, 2009·Journal of the National Cancer Institute·Idan MenashePhilip S Rosenberg
Jul 9, 2009·Journal of the National Cancer Institute·Kathy S AlbainDawn L Hershman
Jul 23, 2009·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Quyen D ChuJonathan Glass
Oct 6, 2009·Critical Reviews in Oncology/hematology·Carol A PariseVincent Caggiano
May 4, 2010·Breast Cancer Research and Treatment·Barbara K DunnKaren A Johnson
Jun 23, 2010·Cancer Causes & Control : CCC·Daixin YinLihua Liu
Jun 25, 2010·Journal of the National Cancer Institute·Ian K KomenakaRobert J Goulet
Nov 26, 2010·Breast Cancer Research : BCR·Allison W KurianChristina A Clarke
Dec 2, 2010·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Nicolien T van RavesteynJeanne S Mandelblatt
Dec 18, 2010·Journal of the National Cancer Institute·Holly R HarrisKarin B Michels
Feb 25, 2011·Journal of the National Cancer Institute·Leslie Bernstein, James V Lacey
Mar 23, 2011·Cancer·Brian L SpraguePolly A Newcomb

❮ Previous
Next ❯

Citations

Jun 3, 2016·Cancer Medicine·Andreana N HolowatyjMichele L Cote
Sep 9, 2016·Journal of Racial and Ethnic Health Disparities·Carol A Parise, Vincent Caggiano
Feb 19, 2016·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Julie A LynchAndrew N Freedman
May 27, 2017·Breast Cancer Research and Treatment·M E RoselandMichael S Simon
Nov 15, 2016·Cancer Control : Journal of the Moffitt Cancer Center·Filipa LynceSusan T Vadaparampil
Sep 27, 2019·Frontiers in Oncology·Tanya Agurs-CollinsBarbara K Dunn
Jun 9, 2018·Journal of Immigrant and Minority Health·Bianca AugustoSusan T Vadaparampil
Mar 6, 2019·Frontiers in Public Health·Fokhrul HossainRichard Scribner
Jan 27, 2021·Breast Cancer Research and Treatment·Kristin N KellyNeha Goel
Oct 16, 2021·Breast Cancer Research and Treatment·Nicole C LoronaChristopher I Li

❮ Previous
Next ❯

Methods Mentioned

BETA
hormone replacement treatments

Related Concepts

Related Feeds

Cancer Disparities

Cancer disparities refers to differences in cancer outcomes (e.g., number of cancer cases, related health complications) across population groups.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.